GENFIT Announces Publication of the Development and Validation of NIS2+™ in the Journal of Hepatology

Lille ; Cambridge ; Zurich ; May 23, 2023 - GENFIT , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced the... | May 23, 2023

Related Keywords

United Kingdom ,Paris ,France General ,France ,Cambridge ,Cambridgeshire ,Switzerland ,Massachusetts ,United States ,American ,Stephena Harrison ,Stephanie Boyer ,Euronext ,Founder For Pinnacle Clinical Research ,University Of Oxford ,Uncertainties Of The Company ,Biomarkers Consortium ,Founder Of Summit Clinical Research ,Nasdaq ,Foundation For The National Institutes Of Health ,Professor At Sorbonne University ,Radcliffe Department Of Medicine ,Exchange Commission ,Non Alcoholic Steatohepatitis ,Vitro Diagnostic ,Vlad Ratziu ,Sorbonne University ,Pinnacle Clinical Research ,Summit Clinical Research ,Visiting Professor ,Radcliffe Department ,Nasdaq Global Select Market ,Private Securities Litigation Reform Act ,Registration Document ,Invasive Biomarkers ,Metabolic Liver ,National Institutes ,Genfit Stock Exchange ,News ,Information ,Press Release ,Ille ,Zurich ,Bay ,023 ,Genfit ,Iopharmaceutical ,Company ,Edicated ,O ,Improving ,The ,Lives ,F ,Patients ,Ith ,Mare ,End ,Evere ,Liver ,Oday ,Nnounced Gnft Fr0004163111 ,